Cholestyramine
- First approval year
- 1973
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Unknown
- Drug name
- Cholestyramine
- cholestyramine
- Cholestyramine
- cholestyramine light
- Cholestyramine light
- cholybar
- Cholybar
- duolite ap143 resin
- Duolite ap143 resin
- locholest
- Locholest
- locholest light
- Locholest light
- prevalite
- Prevalite
- questran
- Questran
- questran light
- Questran light
- a 3384
- A-3384
- a3384
- A3384
- cholestyramine
- Cholestyramine
- CHOLESTYRAMINE
- CHOLESTYRAMINE [MI]
- CHOLESTYRAMINE [ORANGE BOOK]
- CHOLESTYRAMINE [VANDF]
- Cholestyramine 8 g
- cholestyramine mi
- cholestyramine orange book
- Cholestyramine Powder
- Cholestyramine Powder 4g
- cholestyramine resin
- Cholestyramine Resin
- CHOLESTYRAMINE RESIN
- CHOLESTYRAMINE RESIN [HSDB]
- CHOLESTYRAMINE RESIN [USP MONOGRAPH]
- CHOLESTYRAMINE RESIN [USP-RS]
- cholestyramine resin hsdb
- cholestyramine resin usp monograph
- cholestyramine resin usp rs
- cholestyramine vandf
And 20 more, listed on the interactive page.
- ATC classification codes
- C10AC01
Sources for recorded values
- CAS registry numbers
- 11041-12-6
- ChEMBL ID
- CHEMBL1201625
- PubChem compound IDs
- 70695641
- RxNorm IDs (RxCUI)
- 2447
- FDA ingredient codes (UNII)
- 4B33BGI082
- Applicant
- BRISTOL MYERS
- Approval date
- 3 Aug 1973
- Application number
- NDA016640
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Bile acids sequestering agent
- Action type
- SEQUESTERING_AGENT
- Target
- Bile acids
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Smoldering Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003073
- Subject identifier
- D000075122
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Heart Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003777
- Subject identifier
- D006331
- Condition
- Graves Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004237
- Subject identifier
- D006111
- Condition
- Nephrotic Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004255
- Subject identifier
- D009404
- Condition
- Hypothyroidism
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004705
- Subject identifier
- D007037
- Condition
- Hyperlipoproteinemia Type II
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004911
- Subject identifier
- D006938
- Condition
- Hyperthyroidism
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009189
- Subject identifier
- D006980
- Condition
- Myocardial Ischemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001375
- Subject identifier
- D017202
- Condition
- Hypercholesterolemia
- Highest recorded phase
- 4
- Condition identifier
- HP:0003124
- Subject identifier
- D006937
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition
- Lipid Metabolism Disorders
- Highest recorded phase
- 3
- Condition identifier
- Orphanet:309005
- Subject identifier
- D052439
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0003073
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004237
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004255
- Condition identifier
- EFO_0004705
- Condition identifier
- EFO_0009189
- Highest recorded phase
- 3
- Condition identifier
- HP_0001513
- Condition identifier
- HP_0002014
- Condition identifier
- HP_0002014
- Highest recorded phase
- 4
- Condition identifier
- HP_0003124
- Condition identifier
- HP_0003124
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004425
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005010
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005311
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005364
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005377
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005420
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0013209
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015183
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021661
- Highest recorded phase
- 2
- Event
- abdominal discomfort
- Reports
- 15
- Reporting signal score
- 10.052
- Event
- abdominal pain
- Reports
- 24
- Reporting signal score
- 10.6185
- Event
- acidosis hyperchloraemic
- Reports
- 3
- Reporting signal score
- 11.4907
- Event
- alanine aminotransferase increased
- Reports
- 21
- Reporting signal score
- 22.0123
- Event
- anencephaly
- Reports
- 3
- Reporting signal score
- 11.9075
- Event
- aspartate aminotransferase increased
- Reports
- 20
- Reporting signal score
- 22.136
- Event
- bile acid malabsorption
- Reports
- 4
- Reporting signal score
- 21.7501
- Event
- blood alkaline phosphatase increased
- Reports
- 17
- Reporting signal score
- 28.711
- Event
- blood lactate dehydrogenase increased
- Reports
- 7
- Reporting signal score
- 9.53983
- Event
- choking
- Reports
- 12
- Reporting signal score
- 31.8768
- Event
- cholangitis sclerosing
- Reports
- 4
- Reporting signal score
- 11.8919
- Event
- cholecystitis infective
- Reports
- 7
- Reporting signal score
- 25.2726
- Event
- cholelithiasis
- Reports
- 15
- Reporting signal score
- 27.2396
- Event
- cholestasis
- Reports
- 9
- Reporting signal score
- 11.6085
- Event
- colitis
- Reports
- 11
- Reporting signal score
- 13.4342
- Event
- crohn's disease
- Reports
- 11
- Reporting signal score
- 10.5406
- Event
- dehydration
- Reports
- 19
- Reporting signal score
- 12.553
- Event
- dermatomyositis
- Reports
- 5
- Reporting signal score
- 14.406
- Event
- diarrhoea
- Reports
- 62
- Reporting signal score
- 31.53
- Event
- drug hypersensitivity
- Reports
- 26
- Reporting signal score
- 10.4047
- Event
- eye disorder
- Reports
- 7
- Reporting signal score
- 9.98956
- Event
- flatulence
- Reports
- 9
- Reporting signal score
- 11.6774
- Event
- foetal heart rate abnormal
- Reports
- 3
- Reporting signal score
- 10.1987
- Event
- foreign body in throat
- Reports
- 3
- Reporting signal score
- 12.8016
- Event
- gamma-glutamyltransferase increased
- Reports
- 12
- Reporting signal score
- 16.5455
And 22 more, listed on the interactive page.
- NCT00000461
- NCT00000463
- NCT00000488
- NCT00000594
- NCT01239459
- NCT01863888
- NCT02046629
- NCT06141473
- NCT02890992
- NCT03510884
- NCT03303053
- NCT03510715
- NCT05014646
- Dose
- 8.78 grams (1 pouch or scoopful)
- Route
- Oral
- How often
- Once or twice daily (can be administered 1 to 6 doses per day)
Conditions of use
- Must be mixed with water or other fluids before ingesting
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- 0245-0036
- 11788-150
- 24658-266
- 24658-270
- 24658-271
- 27241-134
- 33342-293
- 33342-319
- 42571-508
- 42806-265
- 42806-266
- 42806-267
- 42806-269
- 42806-270
- 42806-271
- 49884-465
- 49884-466
- 49884-936
- 49884-937
- 51224-009
- 51224-011
- 62135-008
- 62135-937
- 67877-298
- 67877-422
And 14 more, listed on the interactive page.
Related records
Trials (27)
- A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles
- A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
- A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study
- A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
- A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
- An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale
- Double-blind, Randomised Study of A3384 in BAM/BAD
- Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia
- Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
- Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
- Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
- Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
- Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
- Harvard Atherosclerosis Reversibility Project (HARP)
- Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Approved for (3)
- Cardiovascular disorder
- Hypothyroidism
- Nephrotic syndrome
In development for (12)
- Coronary artery disorder Phase 3
- Familial hypercholesterolemia Phase 3
- Graves disease Phase 3
- Heart disorder Phase 3
- Hyperthyroidism Phase 3
- Inherited lipid metabolism disorder Phase 3
- Kidney disorder Phase 1
- Multiple sclerosis Phase 3
- Myocardial infarction Phase 3
- Myocardial ischemia Phase 3
- Short bowel syndrome Phase 2
- Smoldering plasma cell myeloma Phase 2